首页> 美国卫生研究院文献>The Journal of Biological Chemistry >LPS Impairs Phospholipid Synthesis by Triggering β-Transducin Repeat-containing Protein (β-TrCP)-mediated Polyubiquitination and Degradation of the Surfactant Enzyme Acyl-CoA:Lysophosphatidylcholine Acyltransferase I (LPCAT1)
【2h】

LPS Impairs Phospholipid Synthesis by Triggering β-Transducin Repeat-containing Protein (β-TrCP)-mediated Polyubiquitination and Degradation of the Surfactant Enzyme Acyl-CoA:Lysophosphatidylcholine Acyltransferase I (LPCAT1)

机译:LPS通过触发包含β-转导蛋白重复序列​​的蛋白(β-TrCP)介导的多聚泛素化和表面活性剂酶Co-Co:LysophosphatidylcholineAcyltransferase I(LPCAT1)的降解来损害磷脂的合成。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a relatively newly described and yet indispensable enzyme needed for generation of the bioactive surfactant phospholipid, dipalmitoylphosphatidylcholine (DPPtdCho). Here, we show that lipopolysaccharide (LPS) causes LPCAT1 degradation using the Skp1-Cullin-F-box ubiquitin E3 ligase component, β-transducin repeat-containing protein (β-TrCP), that polyubiquitinates LPCAT1, thereby targeting the enzyme for proteasomal degradation. LPCAT1 was identified as a phosphoenzyme as Ser178 within a phosphodegron was identified as a putative molecular recognition site for glycogen synthase kinase-3β (GSK-3β) phosphorylation that recruits β-TrCP docking within the enzyme. β-TrCP ubiquitinates LPCAT1 at an acceptor site (Lys221), as substitution of Lys221 with Arg abrogated LPCAT1 polyubiquitination. LPS profoundly reduced immunoreactive LPCAT1 levels and impaired lung surfactant mechanics, effects that were overcome by siRNA to β-TrCP and GSK-3β or LPCAT1 gene transfer, respectively. Thus, LPS appears to destabilize the LPCAT1 protein by GSK-3β-mediated phosphorylation within a canonical phosphodegron for β-TrCP docking and site-specific ubiquitination. LPCAT1 is the first lipogenic substrate for β-TrCP, and the results suggest that modulation of the GSK-3β-SCFβTrCP E3 ligase effector pathway might be a unique strategy to optimize dipalmitoylphosphatidylcholine levels in sepsis.
机译:酰基辅酶A:溶血磷脂酰胆碱酰基转移酶1(LPCAT1)是相对较新描述的,但是生成生物活性表面活性剂磷脂二棕榈酰磷脂酰胆碱(DPPtdCho)所必需的酶。在这里,我们显示脂多糖(LPS)使用Skp1-Cullin-F-box泛素E3连接酶成分,含β-转导蛋白重复的蛋白(β-TrCP)引起LPCAT1降解,即多泛素化LPCAT1,从而将蛋白酶靶向于蛋白酶体降解。 LPCAT1被鉴定为磷酸酶,而磷酸化副产物中的Ser 178 被鉴定为糖原合酶激酶3β(GSK-3β)磷酸化的假定分子识别位点,该酶募集了β-TrCP对接。 β-TrCP在受体位点(Lys 221 )泛素化LPCAT1,而用Arg取代了LPCAT1多聚泛素化取代Lys 221 。 LPS极大地降低了免疫反应性LPCAT1的水平,并损害了肺表面活性剂的力学性能,而siRNA分别克服了这种影响,使之向β-TrCP和GSK-3β或LPCAT1基因转移。因此,LPS似乎可以通过GSK-3β介导的规范化磷酸腺脱氢酶中的GSK-3β介导的磷酸化作用而使LPCAT1蛋白不稳定,从而实现β-TrCP对接和位点特异性泛素化。 LPCAT1是β-TrCP的第一个脂肪生成底物,结果表明,调节GSK-3β-SCFβ TrCP E3连接酶效应子途径可能是优化脓毒症中二棕榈酰磷脂酰胆碱水平的独特策略。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号